|
| Status |
Public on Dec 30, 2016 |
| Title |
A. NT, biological rep3 |
| Sample type |
RNA |
| |
|
| Source name |
PANC-1 non-transfected
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: PANC-1
treatment: non-transfected
cell line origin: pancreatic carcinoma
|
| Treatment protocol |
Cells were transfected with 20 nM miRNA mimics (mirVana, Ambion) using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen).
|
| Growth protocol |
PANC-1 cells were grown in RPMI-1640 medium supplemented with 10% FCS and 2 mM glutamine.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
72 hours after transfection total RNA was extracted using TRIzol reagent (Invitrogen).
|
| Label |
biotin
|
| Label protocol |
cDNA synthesis, amplification and biotin labeling were performed using the GeneChip® WT PLUS Reagent kit (Affymetrix).
|
| |
|
| Hybridization protocol |
Hybridization was performed using the GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix). Hybridization was performed for 16 hours at 45° at 60 rpm. Arrays were washed in the GeneChip® Fluidics station FS 450 (Affymetrix).
|
| Scan protocol |
Affymetrix GeneChip® Scanner 3000 7G.
|
| Description |
Lipofectamine RNAiMAX only
|
| Data processing |
Partek Genomics Suite 6.6. Robust Multiarray Average (RMA) algorithm was used for background correction of probe intensities, gene level expression were summarized from the corrected intensities and then quantile normalized.
probe group file: HuEx-1_0-st-v2.r2.pgf
meta-probeset file: HuEx-1_0-st-v2.r2.dt1.hg18.core.mps
|
| |
|
| Submission date |
Dec 28, 2016 |
| Last update date |
Dec 30, 2016 |
| Contact name |
Gerald W Verhaegh |
| E-mail(s) |
[email protected]
|
| Phone |
+31-24-3610510
|
| Organization name |
Radboudumc
|
| Department |
Urology
|
| Lab |
URL
|
| Street address |
Geert Grooteplein Zuid 28
|
| City |
Nijmegen |
| ZIP/Postal code |
6525GA |
| Country |
Netherlands |
| |
|
| Platform ID |
GPL5175 |
| Series (1) |
| GSE92988 |
Expression data from microRNA-520f transfected PANC-1 pancreas carcinoma cells. |
|
